Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × lifileucel × 1 year × Clear all

Phase

Status

Recruiting 4 Active not recruiting 2 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

pembrolizumab 210 Nivolumab 149 Cyclophosphamide 116 Cisplatin 109 Paclitaxel 107 Carboplatin 106 Radiotherapy 79 Dexamethasone 78 Ipilimumab 76 Gemcitabine 76 atezolizumab 65 Docetaxel 62 Fluorouracil 58 Blood Specimen Collection 54 Bevacizumab 53 Doxorubicin 52 Prednisone 50 Lenalidomide 47 Etoposide 47 Rituximab 46 Standard of Care 45 fludarabine 44 Cytarabine 44 Oxaliplatin 43 Cetuximab 40 Trastuzumab 39 Surveys and Questionnaires 39 Pemetrexed 39 lenvatinib 37 fludarabine phosphate 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02360579 2025-12-09

LN-144

Iovance Biotherapeutics, Inc.

Phase 2 Completed

220 enrolled 15 charts 1 FDA

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡